2型糖尿病对黑色素瘤复发与死亡率的影响:性别与分期特异性丹麦队列研究
该基于丹麦2004-2022年诊断的30,365例黑色素瘤患者的队列研究显示,在局部期黑色素瘤男性中,2型糖尿病与更高的5年复发风险(15.0% vs 8.3%,aHR 1.30,95%CI 1.08-1.56)和黑色素瘤特异性死亡率(8.5% vs 4.2%,aHR 1.28,95%CI 1.00-1.64)相关;女性及晚期患者中未见此预后影响。
要点
- 局部期黑色素瘤男性合并2型糖尿病者复发和黑色素瘤特异性死亡风险更高。
- 女性局部期及两性晚期黑色素瘤患者中,2型糖尿病未见显著预后影响。
- 建议对早期黑色素瘤合并2型糖尿病的男性加强监测。
核心结论
- 2型糖尿病与局部期黑色素瘤男性较差的预后相关,而在女性及更晚期疾病患者中未观察到预后影响。
研究设计与样本
- 基于丹麦2004-2022年诊断的所有黑色素瘤患者的 population-based 队列研究,排除既往癌症或1型糖尿病患者。
- 共纳入30,365例黑色素瘤患者,其中男性14,343例(1,195例合并2型糖尿病),女性16,022例(816例合并2型糖尿病)。
- 按AJCC分期(I-II期局部、III期区域、IV期转移)和性别分层,采用竞争风险模型估计调整风险比(aHR),调整年龄、合并症、日历年及诊断分期。
主要发现
- 局部期黑色素瘤男性中,2型糖尿病与更高的5年复发风险相关(15.0% vs 8.3%,aHR 1.30,95%CI 1.08-1.56)。
- 局部期黑色素瘤男性中,2型糖尿病与更高的5年黑色素瘤特异性死亡风险相关(8.5% vs 4.2%,aHR 1.28,95%CI 1.00-1.64)。
- 局部期黑色素瘤女性中,2型糖尿病相关风险差异较不明显,调整后无关联:复发aHR 1.04(95%CI 0.78-1.38),黑色素瘤特异性死亡aHR 1.10(95%CI 0.75-1.61)。
- 对于区域期或转移性黑色素瘤,两性中2型糖尿病均无预后影响。
临床怎么用
- 对早期(局部期)黑色素瘤合并2型糖尿病的男性患者,应考虑更密切的监测和个体化护理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of both melanoma and type 2 diabetes (T2D) is increasing. Recent studies suggest that T2D is associated with a more advanced melanoma stage at diagnosis, but its impact on melanoma prognosis remains unclear. OBJECTIVES: To examine the impact of T2D on sex-specific and stage-specific melanoma recurrence, melanoma-specific mortality and overall mortality. METHODS: This population-based cohort study included all patients diagnosed with melanoma in Denmark between 2004 and 2022, excluding those with prior cancer or type 1 diabetes. The impact of T2D on melanoma recurrence, melanoma-specific mortality and overall mortality was assessed by stage [American Joint Committee on Cancer stage I-II (localized), stage III (locoregional) and stage IV (metastatic)] and stratified by sex. Cumulative incidence proportions and risk differences (RDs) were estimated. Furthermore, regression analyses using competing-risk models to estimate adjusted hazard ratios (aHRs) were applied, adjusting for age, comorbidity, calendar year and stage at diagnosis. Patients were followed from the date of melanoma diagnosis until death, emigration or the end of the study period (31 December 2024). RESULTS: This study included 30,365 individuals diagnosed with melanoma; 14,343 were men (1195 with T2D), and 16,022 were women (816 with T2D), with higher event frequencies in men than women. Among men with localized melanoma, T2D was associated with higher 5-year risks of recurrence (15.0% vs. 8.3%, aHR 1.30, 95% confidence interval (CI) 1.08-1.56) and melanoma-specific mortality (8.5% vs. 4.2%, aHR 1.28, 95% CI 1.00-1.64). Among women with localized melanoma, the T2D-associated RDs were less pronounced, and no associations were observed after adjustment: recurrence aHR 1.04 (95% CI 0.78-1.38) and melanoma-specific mortality aHR 1.10 (95% CI 0.75-1.61). For both sexes with either locoregional or metastatic melanoma, T2D had no prognostic impact. CONCLUSIONS: T2D was associated with poorer prognosis among men with localized melanoma, whereas no prognostic impact was observed among women or patients with more advanced disease. These findings indicate the need for closer monitoring of men with early-stage melanoma and T2D and for further studies to clarify underlying mechanisms and the potential benefits of optimized diabetes management. Melanoma is a type of skin cancer. Type 2 diabetes (T2D) is a disease where the body cannot control blood sugar levels. Both are becoming more common around the world. We wanted to find out whether having T2D changes the chances of melanoma coming back. We did this study in Denmark. We included everyone diagnosed with melanoma between 2004 and 2022. We compared what happened to people with melanoma who had T2D and those who did not. We then checked whether any differences depended on whether they were a woman or a man. Finally, we checked whether having early-stage or late-stage melanoma made a difference. We found that men with early-stage melanoma and T2D had a higher risk of melanoma coming back. They also had a higher risk of dying from melanoma compared with men without T2D. T2D did not appear to increase the risk of melanoma coming back in women. It also did not appear to increase the risk of melanoma coming back in patients with late-stage melanoma. Our results suggest that men who have both T2D and early-stage melanoma should be carefully monitored. They should also have personalized care. We now need to understand why T2D has a bigger effect on men with early melanoma. This will help to improve treatment so more people can recover from melanoma in the future.
引用
- Lyngstrand JE, Røssell EL, Bønnelykke-Behrndtz ML, et al. The impact of type 2 diabetes on sex-specific and stage-specific melanoma recurrence and mortality: a Danish cohort study, 2004-2024. Br J Dermatol. 2026. PMID: 41831481. doi:10.1093/bjd/ljag097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。